Skip to main content

Silencing of hypothalamic FGF11 prevents diet-induced obesity


Fibroblast growth factor 11 (FGF11) is a member of the intracellular fibroblast growth factor family. Here, we report the central role of FGF11 in the regulation of metabolism. Lentiviral injection of Fgf11 shRNA into the arcuate nucleus of the mouse hypothalamus decreased weight gain and fat mass, increased brown adipose tissue thermogenesis, and improved glucose and insulin intolerances under high-fat diet conditions. Fgf11 was expressed in the NPY–expressing neurons, and Fgf11 knockdown considerably decreased Npy expression and projection, leading to increased expression of tyrosine hydroxylase in the paraventricular nucleus. Mechanistically, FGF11 regulated Npy gene expression through the glycogen synthase kinase 3–cAMP response element-binding protein pathway. Our study defines the physiological significance of hypothalamic FGF11 in the regulation of metabolism in response to overnutrition such as high-fat diet.


The prevalence of obesity and overweight, which are induced by imbalance between energy intake and expenditure, has increased considerably over the decades [1, 2]. The family of fibroblast growth factors (FGFs) consists of 22 members, which are classified into intracellular FGFs (iFGFs), canonical paracrine and autocrine FGFs, and endocrine FGFs depending on their mechanism of action [3, 4]. While canonical and endocrine FGFs are secreted into circulation and act via FGF receptors (FGFRs), iFGFs such as FGF11–FGF14 are acting independently of FGFRs [5, 6]. Mounting evidence suggests that some FGFs have a critical role in the regulation of energy balance including glucose, lipid metabolism, and food intake, suggesting FGFs as therapeutic targets for the treatment of obesity [4]. Central administration of FGF19, endocrine FGF subfamily, reduces the neuronal activity of neurons co-expressing neuropeptide Y (NPY) and agouti-related peptide (NPY/AgRP), thereby improving glucose metabolism and decreasing body weight of mice fed high-fat diet (HFD) [7]. Single intracerebroventricular injection of FGF19 increases glucose disposal rate and ameliorates glucose tolerance in ob/ob mice, which lacks gene responsible for the production of leptin and becomes profoundly obese [8]. Adipocyte-specific FGF21, which is endocrine FGF subfamily, knockout mice exhibit the inhibition of white adipose tissue browning in adaptive thermogenesis, and central infusion of FGF21 in obese rats increases insulin-induced suppression of hepatic glucose production and gluconeogenic expression, which in turn increases energy expenditure and insulin sensitivity. [9, 10]. FGF1-knockout mice show aberrant adipose tissue expansion with severe diabetic phenotypes upon HFD feeding, and central administration of FGF1 in wild-type mice suppresses food intake and inhibits FGFR1-containing glucose-sensitive neurons [11, 12]

Recently, it was reported that FGF11 interacts with HIF-1α to induce hypoxia [13], and Fgf11 knockdown reduces the expression of peroxisome proliferator–activated receptor gamma, thereby inhibiting adipogenesis [14]. However, the function of FGF11, especially its central role in the regulation of whole-body metabolism, remains unknown.

Hypothalamus is one of the most important brain areas that govern metabolism including food intake as well as glucose and energy metabolism [15, 16]. Two major neuronal populations located in the arcuate nucleus of the hypothalamus (ARC) play a fundamental role in regulating metabolism: (i) orexigenic NPY/AgRP co-expressing neurons, which promote anabolism [17, 18], and (ii) anorexigenic neurons co-expressing pro-opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript (CART), which induce catabolism [19,20,21]. These neurons integrate peripheral signals to convey them to the second-order neurons in the paraventricular nucleus (PVN) and deliver multiple signals into their areas of acting such as the nucleus tractus solitarius, dorsal motor nucleus of the vagus, and the ventrolateral medulla in the hindbrain, thereby playing an indispensable role in the regulation of energy metabolism [15, 22, 23]. Numerous studies have demonstrated that NPY/AgRP co-expressing neurons are critical for metabolic functions including food intake, energy expenditure, and thermogenesis [24,25,26,27,28].

Here, we discovered the effect of central Fgf11 knockdown on multiple parameters involved in whole-body metabolism. The present study contributes to our understanding of the metabolic role of FGF11 in the ARC, highlighting FGF11 as a potential target for the treatment of obesity.

Materials and methods

Animal models

Male C57BL/6 mice were purchased from Koatech and housed (one per cage) in individually ventilated cages under a 12-h light/dark cycle (lights on from 7:00 to 19:00) in a temperature- and humidity-controlled room with ad libitum access to water and normal-chow diet (NCD) (LabDiet, Inc., 38057) or HFD (60% kcal from fat; Research Diets, Inc., D12492). Food intake and body weight were observed daily just before the onset of the dark cycle as previously described [29]. The mice were divided into the following groups: control shRNA injected C57BL/6 mice group (shCon); shFgf11-expressing shRNA injected C57BL/6 mice group (shFgf11).

Generation of lentiviruses

Lenti-X 293 T cells (Clontech, 632180) were seeded on 100 mm dishes and transfected with psPAX2 packaging plasmid (6 μg), pMD2.G envelope plasmid (2 μg), and GPIZ constructs (8 μg, green fluorescent protein (GFP), carrying either control (Dharmacon, RHS4346) or Fgf11-targeting shRNA using TurboFect (Thermo Scientific, R0531) following the manufacturer’s instructions. To prevent off-target effects, 2 different shRNA plasmids targeting both A and B isoforms of Fgf11 (Dharmacon, VGM5520-200406248 and VGM5520-200407071) were selected after testing 6 different shRNA plasmids for mouse Fgf11. Culture medium containing lentiviruses was harvested and filtered through 0.45 μm syringe filters (Millipore, SLHV033RS) as previously described [29]. To obtain concentrated viruses, 4 successive rounds of ultracentrifugation were carried out in the same ultra-clear centrifuge tubes (Beckman, 344058) at 43,000 × g for 120 min at 4 °C [30]. After final centrifugation, pellets were gently resuspended in saline. The titers of lentiviral stocks were determined by flow cytometry [31]; that of control virus was 6.76 × 1010 and that of shFgf11-expressing lentivirus was 6.62 × 1010 IU/ml. The concentrated viruses were aliquoted and stored at − 80 °C.

Stereotaxic surgery

Seven-week-old C57BL/6 mice were acclimated for a week and were anesthetized with 10 ml/kg of body weight of a mixture of Zoletil, Rumpun, and saline 25 min before surgery. Lentiviruses were injected at a speed of 0.5 µl/min (1.32 × 108 IU/2 μl on each side) with a microliter syringe (Hamilton, 7768) using the following coordinates: 1.4 mm posterior to bregma; 6.2 mm ventral; 0.35 mm bilateral targeting the ARC [29].

Insulin tolerance test (ITT) and glucose tolerance test (GTT)

ITT was conducted 4 weeks after virus injection and GTT 5 weeks after virus injection. Mice were habituated to daily intraperitoneal injections of isotonic saline 3 days before each tolerance test. All procedures were started at 10:00 and performed with reference to general procedures [32, 33]. For ITT, 6 h-fasted mice were injected with 1.0 U insulin/kg (Sigma, Cat#I9278) and blood was collected from the tail vein at the designated times and used to measure glucose with a glucose monitor (Roche, Accu-Chek Active meter). GTT was performed using 16 h-fasted mice by an i.p. injection of 1.5 g/kg glucose (Sigma, Cat#G8270) and blood glucose was assessed as in ITT.

Determination of brown adipose tissue (BAT) temperature

To evaluate BAT thermogenesis, an infrared camera (FLIR E60, FLIR Systems, Inc.) was used with an intra-red resolution of 320 × 240 pixels. To rule out stress-induced thermogenesis, mice were neglected for an hour while being able to move freely. BAT temperature of each mouse was measured at least 3 times for each round, and the average temperatures from each of 5 rounds were used for analysis.

Determination of heat generation, O2 consumption (VO2), CO2 production (VCO2), respiratory exchange ratio (RER), and total locomotor activity

Two weeks after ARC Fgf11 knockdown with HFD feeding, indirect calorimetry was performed using metabolic chambers of Comprehensive Lab Animal Monitoring Systems (CLAMS; Columbus Instruments). Mice were housed individually with free access to water and HFD in metabolic chambers Mice were acclimated for 24 h before metabolic assessment. After acclimation, heat generation, VO2, VCO2, RER, and locomotor activity were measured using an Oxymax system (Columbus Instruments). VO2, VCO2, and heat production were assessed every 12 min during 24 h and were normalized to body weight; RER was calculated as VCO2/VO2. Locomotor activity was determined by measuring interruptions in the infrared beams (total X- and Z-beam breaks).

In situ hybridization

In situ hybridization for the simultaneous detection of Fgf11 and Npy in the ARC was performed using an RNAscope fluorescent multiplex kit (Advanced Cell Diagnostics; ACD). Brains were dissected from three mice, and were rapidly embedded in FSC 22 Frozen Section Media (Lecia, 3801480) and frozen on dry ice. Fresh frozen coronal Sections (20 μm) were cut on a cryostat (Lecia, CM3050S) and dual-labeled for the mRNA of Fgf11 (ACD, 701) and Npy (ACD, 313321-C2) following the manufacturer’s protocol. The Fgf11 antisense probe targeted the region 888–1891 of the mouse Fgf11 transcript variant 1 (NM_010198.3), but was cross-reactive with all the other transcript variants (NM_001291104.2, NM_001362623.1, NM_001362624.1). The Fgf11 sense probe (ACD, 843141) was used as a negative control, and the negative control probe (ACD, 320751) recognizing dihydrodipicolinate reductase, DapB (a bacterial transcript), was also used in parallel with the target probes. Fluorescent in situ hybridization images were taken using an LSM 780 or LSM 800 confocal laser-scanning microscope (Carl Zeiss) with maximal signal separation.


The processing, embedding, cryosectioning, and immunofluorescence staining of brain tissue were performed as previously described [34]. The final dilutions of primary antibodies—sheep anti-NPY (1:1000; Abcam, ab6173) and mouse anti-TH (1:1000; Immunostar, 22941)—were 1:1000. The following secondary antibodies were used (both at 1:500): Cy3-conjugated donkey anti-sheep IgG (1:500; Jackson ImmunoResearch, 713–165-147) and AlexaFluor 488–conjugated anti-mouse IgG (1:500; Jackson ImmunoResearch, 715-545-150). Sections were incubated for 5 min at room temperature with 1 μg/mL Hoechst 33342 (Invitrogen, H3570) in phosphate-buffered saline for nuclear staining, mounted on glass slides, and coverslipped with Vectashield Mounting Medium (Vector Laboratories, H-1000). From each mouse (at least 3 mice in total), 3–5 ARC or PVN sections were analyzed using LSM 780 or LSM 800 with maximal signal separation.

Measurement of immunofluorescence intensity

Standardized settings for image acquisition and processing intensity were performed for relative quantification of NPY and TH fluorescence. To obtain values for NPY immunofluorescence intensity in the ARC and PVN, morphological boundaries of each area were drawn on images. For TH immunofluorescence intensity in the TH neuron, the cell type-specific outlines were plotted with the corresponding gray-scaled TH immunofluorescence images. Single measurements of fluorescence intensity were performed using Image J software (National Institutes of Health, US). NPY fluorescence intensity for each mouse hypothalamic region were averaged from six independent measurements. TH fluorescence intensity for each TH neuron were averaged from four independent measurements. The fluorescence intensity of NPY and TH was plotted using arbitrary units ranging from 0 to 3. NPY-positive axon terminals adjacent within 1.5 µm from TH positive neurons were counted for counting the number of NPY-positive boutons.

Quantitative RT-PCR analysis of mRNA expression

Total RNA was isolated from cells and tissues using Trizol reagent (Invitrogen, 15596018). The RNA pellet was dissolved in nuclease-free water (Promega, P1193) and total RNA concentration was determined using a NanoDrop spectrophotometer (DeNovix, DS-11). Total RNA, reaction buffer, and GoScript Reverse Transcriptase (Promega, A5004) were mixed in a total volume of 20 μl and reverse transcription was carried out in a thermal cycler (Bio-Rad, C1000) at 25 °C for 5 min, 42 °C for 60 min, and 70 °C for 15 min. Real-time PCR was performed with a SYBR Green PCR kit (TaKaRa Biotechnology, RR820A) in a qPCR machine (Bio-Rad, CFX96) for 40 cycles (95 °C for 10 s, 60 °C for 30 s). The following primers were synthesized by Integrated DNA Technologies: Cart Forward, 5′-CGAGAAGAAGTACGGCCAAGTCC-3′; Cart Reverse, 5′-GGAATATGGGAACCGAAGGTGG-3′; Dio2 Forward, 5′-TGCCACCTTCTTGACTTT-3′; Dio2 Reverse, 5′-GTTTCCGGTGCTTCTTAACC-3′; Fgf11 Forward, 5′-TCGTCACCAAACTGTTCTGC-3′; Fgf11 Reverse, 5′-GCCATGTAGTGACCCAGCTT-3′; Gapdh Forward, 5′-ATCACTGCCACCCAGAAGAC-3′; Gapdh Reverse, 5′-ACACATTGGGGGTAGGAACA-3′; Npy Forward, 5′-CAGAAAACGCCCCCAGAA-3′; Npy Reverse, 5′-AAAAGTCGGGAGAACAAGTTTCATT -3′; Pgc1α Forward, 5′-AGCCGTGACCACTGACAACGAG-3′; Pgc1α Reverse, 5′-GCTGCATGGTTCTGAGTGCTAAG-3′; Pomc Forward, 5′-GAACAGCCCCTGACTGAAAA-3′; Pomc Reverse, 5′-ACGTGGGGGTACACCTTCAC-3′; Prdm16 Forward, 5′-CCGCTGTGATGAGTGTGATG-3′; Prdm16 Reverse, 5′-GGACGATCATGTGTTGCTCC-3′. Relative mRNA expression of each target gene was analyzed by the delta-delta Ct method and normalized to that of Gapdh.

Antibodies and chemical reagents

Target proteins were immunoblotted with the following antibodies: phospho-AKT (Ser473; Cell Signaling Technology [CST], 4060), AKT (CST, 9272), β-catenin active (CST, 8814), β-catenin (CST, 9582), phospho-CAMKII (Thr286; CST, 12,716), CAMKII (CST, 3362), phospho-CREB (Ser133; CST, 9198), phospho-CREB (Ser129; MyBioSource, MBS9406211), CREB (CST, 9197), phospho-ERK (Thr202/Thr204, 4370), ERK (CST, 9107), phospho-FOXO1 (Ser256; CST, 9461), FOXO (CST, 2880), GAPDH (CST, 2118), phospho-GSKα and β (Tyr279 and Tyr216; BD Biosciences, 612313), phospho-GSKα and β (Ser21 and Ser9; CST, 8566), GSKα and β (CST, 5676), HA-tag (CST, 3724), phospho-STAT3 (Tyr705; CST, 9145), and STAT3 (CST, 12640). When indicated, cells were treated with 2-deoxy-D-glucose (2DG; Sigma, D6134) to induce glucoprivation; 2DG was dissolved in DPBS (Corning, 21-031-CVR) or saline. 6-Bromoindirubin-3'-oxime (BIO; Sigma, B1686) was dissolved in dimethyl sulfoxide (Sigma, M81802).

Western blotting

Cells were lysed in 50 mM Tris–HCl, pH 7.4, 250 mM sucrose (Bioshop, SUC507), 5 mM sodium pyrophosphate, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100 (Sigma, T8787), 0.1 mM benzamidine (Sigma, B6506), 1 mM DTT, 0.5 mM PMSF (Sigma, P7626), 50 mM NaF, protease inhibitor cocktail (Calbiochem, 535,140), and phosphatase inhibitor cocktail (Sigma, P5726). Lysates were resolved in SDS–polyacrylamide gels and blotted onto PVDF membranes (Millipore, IPVH00010) for 35 min at 20 V in transfer buffer (25 mM Tris base, pH 7.4, 192 mM glycine, 10% methanol). The membranes were blocked with 5% skim milk for 1 h and incubated with appropriate primary antibodies for 1 h at room temperature or at 4 °C overnight. After 3 washes with TBST buffer (20 mM Tris [Bioshop, TRS001], 125 mM NaCl [Bioshop, SOD001], 0.1% Tween 20 [Sigma, P1379]), each membrane was incubated with appropriate HRP-linked secondary antibody (anti-mouse: CST, 7076S; anti-rabbit: Thermo Scientific, NCI1460KR) and the bands were visualized by using ECL solutions (Thermo Scientific, NCI4080KR; Advansta, K-12045-D50) according to the manufacturer’s instructions. Band intensities were measured and quantified using ImageJ software.

Cell lines

The embryonic mouse hypothalamic mHypoE-N41 (N41; Cellutions Biosystems Inc., CLU121) and mHypoE-N43/5 (N43/5; Cellutions Biosystems Inc., CLU127) cell lines were maintained in DMEM (Sigma, D5796) with 10% fetal bovine serum (Hyclone Laboratories Inc., SH30919.03) and 1% penicillin/streptomycin (Hyclone Laboratories Inc., SV30010) at 37 °C.

2DG and 0-mM glucose treatment

For glucoprivation (2DG) or glucose deprivation (glucose-free), 2DG was added to 25-mM glucose DMEM (Welgene, LM001-07) or 0-mM glucose DMEM (Welgene, LM001-56), was used, respectively. Lenti-X 293T (Clontech, 632180) cells were maintained in DMEM (Hyclone Laboratories Inc., SH30243) under the same conditions as hypothalamic cell lines.

siRNA transfection

N41 and N43/5 cells were seeded in 6-well plates and transfected with ON-TARGETplus mouse scrambled or Fgf11 siRNA comprised of 4 different siRNAs. Scrambled siRNAs (100 nM; Dharmacon, D-001810–10-10–05) or Fgf11 siRNAs (100 nM; Dharmacon, L-045551–01-0010) were transfected using Lipofectamine 3000 for 48 h following the manufacturer’s instructions.

Statistical analysis

All data were reported as means ± standard error of the mean (SEM). Statistical significance was determined by two-tailed t-test or two-way analysis of variance (ANOVA) followed by a Tukey multiple comparison test using GraphPad Prism 8; p values < 0.05 were considered statistically significant.


Hypothalamic ARC Fgf11 knockdown prevents obesity

To investigate the central expression of Fgf11, we tested Fgf11 mRNA expression in multiple brain areas and found that it was expressed in the hypothalamus, hippocampus, cortex, and cerebellum (Additional file 1: Fig. S1). Considering that the hypothalamic ARC is a pivotal brain region that governs metabolism [35, 36], we monitored diverse metabolic parameters after the injection of shFgf11-carrying and GFP-expressing lentivirus into the ARC. Successful ARC lentivirus targeting was confirmed by immunohistochemistry (Fig. 1A). ARC Fgf11 knockdown was confirmed by a significant decrease in ARC Fgf11 mRNA level in comparison with non-silencing shRNA control (Fig. 1B). ARC Fgf11 knockdown had no effect on body weight or food intake of NCD-fed mice (Fig. 1C, D). However, body weight gain of HFD-fed mice was markedly reduced by ARC Fgf11 knockdown, starting from 4 days after lentivirus injection (Fig. 1E). Food intake of ARC Fgf11 knockdown mice fed HFD was also decreased transiently after knockdown (Fig. 1F). HFD did not change Fgf11 mRNA expression levels until 12 weeks but increased them at 16 weeks of HFD (Additional file 1: Fig. S2). While lean mass of ARC Fgf11 knockdown mice fed HFD remained unchanged, fat mass was substantially reduced (Fig. 1G, H). In GTT and ITT, ARC Fgf11 knockdown mice fed HFD showed increased glucose clearance rate and insulin sensitivity as compared with control mice, indicating that ARC Fgf11 knockdown improved the overall systemic glucose homeostasis under HFD conditions (Fig. 1I, J). Altogether, these results suggest that ARC Fgf11 knockdown prevents obesity including overweight, increase in adiposity, and attenuation of glucose metabolism.

Fig. 1
figure 1

Fgf11 knockdown in the ARC decreases body weight and fat mass, and improves glucose metabolism in HFD-fed mice. Adult male C57/BL6 mice were fed HFD for 14 days after bilateral injection of lentivirus expressing shFgf11 and GFP into the ARC. A Coronal section of ARC. GFP indicates lentiviral infection. B mRNA expression of Fgf11 in micro-dissected ARC sample following injection of shFgf11-expressing lentivirus. C Body weight and weight gain of NCD-fed mice during the experimental period. D Food intake and average food intake of NCD-fed mice. E Body weight and weight gain of HFD-fed mice during the experimental period. F Food intake and average food intake of HFD-fed mice. G Lean mass and H fat mass. I Glucose tolerance test (GTT) and J insulin tolerance test (ITT) after lentivirus injection. Data are mean ± SEM; two-tailed t-test was used for statistical analysis. *p < 0.05, **p < 0.01 and ***p < 0.001 (non-silencing shRNA control versus shFgf11). n = 5–16 mice/group

ARC Fgf11 knockdown enhances BAT thermogenesis in HFD-fed mice

To evaluate the effect of ARC Fgf11 knockdown on energy expenditure, we analyzed diverse metabolic parameters including heat generation, O2 consumption (VO2), CO2 production (VCO2), respiratory exchange ratio (RER), and locomotor activity using indirect metabolic calorimetry. ARC Fgf11 knockdown in HFD-fed mice increased heat generation, VO2, and VCO2 compared with control mice in both light and dark period (Fig. 2A–C). ARC Fgf11 knockdown did not affect RER or locomotor activity (Fig. 2D–F). Since locomotor activity of HFD-fed mice was not affected by ARC Fgf11 knockdown, activation of BAT thermogenesis might contribute to the increased heat generation. As expected, BAT temperature of ARC Fgf11 knockdown mice fed HFD was considerably higher than that of control mice (Fig. 2G, H). Furthermore, Fgf11 knockdown mice displayed increased mRNA expression of thermogenic genes including Ucp1, Pgc1α, and Dio2 compared with control mice (Fig. 2I). Taken together, these data indicate that ARC Fgf11 knockdown increases heat generation, O2 consumption, and CO2 production in HFD-fed mice and increases BAT activity by increasing the expression of thermogenic genes.

Fig. 2
figure 2

ARC Fgf11 knockdown increases heat generation, VO2, VCO2, and BAT thermogenesis without changing locomotor activity. Adult male C57BL/6 mice fed HFD for 2 weeks after bilateral injection of shFgf11-expressing lentivirus into the ARC. AF Heat generation, VO2, VCO2, RER, total activity at z-axis (ZTOT), and ambulatory activity at x-axis (XAMB). GH Infra-red images of BAT temperature and max BAT temperature on day 14 post-surgery. I mRNA expression of 4 representative thermogenic markers on day 14 after ARC Fgf11 knockdown: Ucp1, Pgc1α, Dio2, Prdm16. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 (non-silencing shRNA control versus shFgf11). n = 5–10 mice/group

Decreased NPY projection from ARC into the PVN caused by ARC Fgf11 knockdown increases PVN TH expression in HFD-fed mice

To elucidate the mechanism of increased BAT thermogenesis in ARC Fgf11 knockdown mice fed HFD, we investigated changes in hypothalamic neuropeptides NPY, AgRP, POMC, and CART, which are related to energy expenditure and thermogenesis [20, 28, 37, 38]. Of these neuropeptides, only Npy mRNA expression was significantly decreased by Fgf11 knockdown in HFD-fed mice (Fig. 3A–D). Fgf11 knockdown in NCD-fed mice also reduced Npy mRNA expression, while other neuropeptides remained unchanged (Additional file 1: Fig. S3). We determined whether FGF11 is expressed in the NPY-expressing neurons. In situ hybridization showed that Fgf11 mRNA was scattered throughout the ARC, and all Npy mRNA–positive neurons contained Fgf11 mRNA, indicating that Fgf11 was expressed in NPY neurons (Fig. 3E). NPY immunoreactivity was diminished in both the ARC and PVN of ARC Fgf11 knockdown mice (Fig 3. F–I). Since ARC NPY overexpression reduces BAT thermogenesis by decreasing TH expression in the PVN [28], we hypothesized that ARC Fgf11 knockdown activated BAT thermogenesis by inducing PVN TH expression because of a decrease in ARC NPY expression. PVN Th mRNA expression was significantly higher in ARC Fgf11 knockdown mice than in control mice under HFD conditions (Fig. 3J).

Fig. 3
figure 3

A decrease in NPY expression in the ARC by Fgf11 knockdown reduces NPY projection into the PVN, increasing PVN TH expression in HFD-fed mice. AD Neuropeptide expression in mice fed HFD for 2 weeks after ARC Fgf11 knockdown. E Representative confocal images of in situ hybridization of mRNA of Fgf11 and Npy and corresponding DAPI nuclear counterstaining in the ARC. The Fgf11 sense probe was used as a negative control. Arrowheads show Fgf11 mRNA–positive cells. Arrows indicate Npy mRNA–positive cells. Scale bar = 20 μm. F Coronal sections of the ARC and G relative immunofluorescence quantification of ARC of mice fed HFD for 2 weeks after ARC Fgf11 knockdown. H Coronal sections of the PVN and I relative immunofluorescence quantification of PVN of mice fed HFD for 2 weeks after ARC Fgf11 knockdown. Sections were immunostained for NPY; confocal microscopy acquisition settings were the same for both non-silencing shRNA control and shFgf11. Scale bars F 50 μm, H 100 μm. J Th mRNA expression in a micro-dissected sample of the PVN of ARC Fgf11 knockdown mice fed HFD for 2 weeks. K Representative confocal images of double immunostaining for NPY and TH in the PVN 2 weeks after injection of non-silencing shRNA control or Fgf11 shRNA into the ARC and L relative immunofluorescence quantification of TH. Arrows denote NPY-immunoreactive boutons. Scale bar = 5 μm. M Number of NPY-positive axon terminals adjacent to TH neuron. *p < 0.05 and **p < 0.01 (non-silencing shRNA control versus shFgf11). n = 3–10 mice/group

Next, to investigate whether this increase in PVN Th mRNA expression was a direct consequence of reduced NPY expression caused by ARC Fgf11 knockdown in the ARC, we conducted immunohistochemistry to identify whether PVN TH neurons were innervated by ARC NPY neurons and were affected by ARC NPY expression. Double immunostaining for NPY and TH showed that PVN TH-positive neurons were in contact with NPY-immunoreactive boutons in their soma and dendrites of mice fed NCD (Additional file 1: Fig. S4), suggesting that PVN TH neurons were innervated by ARC NPY neurons. The immunoreactivity of TH-positive cell bodies in the PVN was increased in Fgf11 knockdown mice, while the numbers and immunoreactivity of NPY-positive axon terminals adjacent to PVN TH-positive neurons were reduced by ARC Fgf11 knockdown (Fig. 3K–M). These data demonstrate that ARC Fgf11 knockdown reduces ARC NPY expression that upregulates PVN TH expression, thereby increasing thermogenesis of BAT.

FGF11 regulates Npy gene expression in NPY-expressing hypothalamic cells

We further assessed the role of FGF11 in the regulation of Npy gene expression in hypothalamic cell line N41 co-expressing NPY and AgRP. Fgf11 knockdown significantly decreased mRNA expression of Npy but not AgRP in N41 cells (Fig. 4A–C). On the other hand, Fgf11 knockdown in N43/5 cells co-expressing Pomc and Cart did not affect the expression of either gene (Additional file 1: Fig. S5). Of note, overexpression of Fgf11 rescued Fgf11 knockdown–induced decrease in Npy mRNA expression (Fig. 4D, E ). Since Npy expression is induced by low glucose availability [29], we tested whether Fgf11 knockdown attenuates Npy gene induction under low glucose conditions such as glucose-free medium or 2DG treatment. While Fgf11 mRNA expression was unchanged, Npy mRNA expression was considerably increased at both glucose-free medium and 2DG treatment (Fig. 4F–I). Low glucose availability–induced Npy gene expression was blunted by Fgf11 knockdown in glucose-free medium (Fig. 4G), as it was under 2DG treatment (Fig. 4I). In mice, Fgf11 mRNA expression remained unchanged under fasting condition (Additional file 1: Fig. S6). Taken together, these data indicate that Fgf11 regulates Npy gene expression in hypothalamic N41 cells.

Fig. 4
figure 4

FGF11 regulates Npy gene expression. siRNA-mediated Fgf11 knockdown was conducted in NPY/AgRP co-expressing hypothalamic cells. AC mRNA expression of A Fgf11, B Npy, and C AgRP following Fgf11 knockdown in N41 cells. D N41 cells were transfected with empty vector (E/V) or HA-tagged FGF11 and Fgf11 overexpression and knockdown were confirmed by immunoblotting. E Npy mRNA expression after Fgf11 knockdown with Fgf11 overexpression (O/E). N41 cells were exposed to 0 mM glucose (glc) medium with Fgf11 knockdown, and mRNA expression of F Fgf11 and G Npy was measured. N41 cells were treated with 2DG with Fgf11 knockdown and mRNA expression of H Fgf11 and I Npy was evaluated. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, n = 6–11

Fgf11 knockdown decreases CREB activity but increases GSK3 activity in hypothalamic cells

To identify the regulatory molecules involved in FGF11-dependent Npy gene regulation, we investigated the transcription factors responsible for changes in Npy expression following Fgf11 knockdown. Considering that Npy expression is regulated by multiple transcription factors such as CREB, forkhead box protein O1, and signal transducer and activator of transcription 3 [39,40,41,42,43], we assessed the activities of these transcription factors by examining changes in their phosphorylation. Immunoblot analysis showed that none of these transcription factors was affected by Fgf11 knockdown except for CREB phosphorylation (Fig. 5A, B); phosphorylation of CREB at Ser133 is activatory, whereas that at Ser129 is inhibitory [44,45,46,47]. We found that CREB phosphorylation at Ser133 was decreased, while that at Ser129 was increased by Fgf11 knockdown, indicating that CREB activity was markedly reduced by Fgf11 knockdown in the hypothalamic cells (Fig. 5A, B). Next, to identify upstream factors responsible for the changes in CREB phosphorylation by Fgf11 knockdown, we examined the phosphorylation levels of GSK3, protein kinase B, Ca2+/calmodulin-dependent protein kinase II, and extracellular signal-regulated kinases since these kinases are known to regulate the activity of CREB [46, 48,49,50,51,52]. Only the phosphorylation of GSK3 at Tyr279 and Tyr216, corresponding to the active forms of GSK3 α and β, respectively, was increased, while that at GSK3 Ser21 and Ser9 was not changed by Fgf11 knockdown (Fig. 5C, D). Of note, phosphorylation of FYN and PYK2, which are known to control the phosphorylation of GSK3 Tyr216 residue, was unchanged (Additional file 1: Fig. S7) [53]. Phosphorylation of other upstream kinases of CREB was not affected by Fgf11 knockdown (Fig. 5C and E). These data suggest the possibility that Fgf11 might regulates CREB activity through the regulation of GSK3 tyrosine phosphorylation.

Fig. 5
figure 5

Fgf11 knockdown in NPY/AgRP co-expressing hypothalamic cells increases CREB and decreases GSK3 activity. N41 cells were transfected with non-silencing siRNA control or siFgf11 for 48 h. A Western blots of N41 cells: transcription factors of NPY. B Quantitation of immunoblots. C Western blots of the regulators of CREB activity. D, E Quantification of immunoblots. *p < 0.05, **p < 0.01, and ***p < 0.001 (non-silencing siRNA control versus siFgf11). n = 3 or 4

Fgf11 regulates NPY mRNA expression through GSK3-dependent CREB activity

GSK3α and GSK3β inhibition favors CREB phosphorylation at Ser133 [54]. GSK3β reduces CREB binding activity via the phosphorylation of CREB Ser129 [46, 48, 50]. To determine whether Fgf11 knockdown reduces CREB activity via GSK3, we treated N41 cells with BIO, a GSK3 inhibitor [55, 56]. BIO treatment did not affect Fgf11 mRNA expression but increased Npy mRNA expression in a time-dependent manner (Fig. 6A, B). GSK3 inhibition by BIO was confirmed by decreased tyrosine phosphorylation and increased accumulation of β-catenin, which is a GSK3 substrate and is degraded by the β-catenin destruction complex [57] (Fig. 6C, D). Additionally, CREB activity was markedly increased by BIO, as demonstrated by increased CREB Ser133 phosphorylation and decreased CREB Ser129 phosphorylation (Fig. 6C, D).

Fig. 6
figure 6

FGF11 regulates Npy gene expression via GSK3-dependent CREB regulation in NPY/AgRP co-expressing hypothalamic cells. N41 cells were treated with dimethyl sulfoxide (vehicle) or BIO (1 μM) for 1, 3, or 6 h. A, B mRNA expression of Fgf11 and Npy after the treatment of BIO. C, D Western blots of GSK3, β-catenin, and CREB following the treatment of BIO. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001 (vehicle versus BIO). n = 4–6. EH N41 cells were transfected with non-silencing siRNA control or siFgf11 for 48 h, followed by the treatment with vehicle or BIO for 6 h. E, F mRNA expression of Fgf11 and Npy after Fgf11 knockdown with BIO treatment. G, H Western blots of GSK3, β-catenin, and CREB after Fgf11 knockdown with BIO treatment. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001, n = 3–9

To investigate whether the decrease in Npy mRNA expression following Fgf11 knockdown is due to GSK3-dependent CREB activity, Fgf11-knockdown N41 cells were treated with BIO. The inhibition of Npy mRNA expression under Fgf11 knockdown was rescued by BIO (Fig. 6E, F). BIO significantly decreased Fgf11 knockdown–induced GSK3 tyrosine phosphorylation, as opposed to accumulation of β-catenin (Fig. 6G, H). Importantly, concomitant with the recovery of Npy expression, CREB activity decreased by Fgf11 knockdown was recovered by GSK3 inhibition, as shown by an increase in pSer133 and a decrease in pSer129 levels (Fig. 6G, H). These data demonstrate that FGF11 regulates Npy gene expression via GSK3-dependent CREB activity.


FGFs is one of the key players in the regulation of energy balance. However, the function of FGF11 in metabolism remains largely unknown compared with those of other FGFs. Here, we report that hypothalamic FGF11 knockdown improved metabolic features under high-fat conditions.

It has been unknown for the role of FGF11 in regulation of glucose homeostasis. Our study showed that FGF11 knockdown in the hypothalamus improves glucose and insulin intolerance. Previous studies noted that the inhibition of the hypothalamic NPY upstream signaling pathway increases insulin secretion [58, 59] and NPY neuron-specific insulin receptor deficient mice showed impaired glucose homeostasis [60]. Although further study needs to clarify the mechanisms underlying the glucose metabolism and insulin sensitivity regulated by hypothalamic FGF11, it is possible that FGF11 in the NPY neurons could be involved in insulin functions for glucose homeostasis.

Unlike other FGF family such as canonical and endocrine FGFs, the expression of FGF11 family such as FGF12, 13, and 14 is confined to hypothalamic parenchyma including dorsomedial nucleus, ventromedial nucleus, and ARC, not tanycytes [61]. We demonstrated that FGF11 is expressed in the hypothalamus, especially in the NPY neurons in the ARC. This expression pattern reflects the feature of FGF11 family that does not mediate their actions via FGF receptors since FGF receptors in the hypothalamus are mainly expressed in the β-tanycytes [61].

We found that FGF11 regulates Npy gene expression by regulating GSK3-dependent CREB activity in the hypothalamus. The activity of GSK3 is mainly controlled by its serine phosphorylation Ser21 in GSK3α and Ser9 in GSK3β [48]. The serine phosphorylation of GSK3 facilitates the action of its N-terminal tail as a pseudosubstrate, hindering binding of primed substrates [62]. GSK3 tyrosine phosphorylation (Tyr 279 in GSK3α and Tyr216 in GSK3β) occurs by auto-phosphorylation during translation and is associated with increased kinase activity [63]. Interestingly, Fgf11 knockdown did not affect the phosphorylation of GSK3 at serine residue in our study, but changed the phosphorylation at Tyr279 and Tyr216. Therefore, FGF11 might be involved in the regulation of the tyrosine phosphorylation of GSK3α and GSK3β to regulate GSK3 activity.

It has been unknown which physiological conditions regulate the gene expression of Fgf11. In our study, we first demonstrated that hypothalamic Fgf11 gene expression was significantly increased by 16-week-HFD, but not by fasting. According to a previous study, the full manifested features of obesity develop after 16 weeks of HFD [64]. Therefore, the expression of Fgf11 can be regulated under physiological conditions such as fully developed obesity although it is not clear whether the increase in Fgf11 gene expression is a cause or result of the development of obesity. Considering the role of hypothalamic FGF11 in the whole-body metabolism, it is likely that the increase in Fgf11 gene expression is associated with the progression of obesity. Future studies are needed to elucidate the mechanism(s) by which the hypothalamic Fgf11 is regulated by HFD or other physiological conditions.

Another point is that Fgf11 knockdown in N41 cells did not change the activity of the kinases such as FYN or PYK2, which is known to regulate the activity of GSK3 [53]. FGF11 is not a kinase [3, 5, 6], and it has an N-terminal nuclear localization signal and directly acts with HIF-1α in the nucleus [13]. Our immunoprecipitation analysis in N41 cells indicates that FGF11 does not directly bind to GSK3 (data not shown). It is possible that FGF11 regulates the tyrosine phosphorylation of GSK3 indirectly. Although further study will be needed to understand how FGF11 regulates the phosphorylation of GSK3 and the related regulatory mechanisms, our results unveil a previously unknown role of FGF11 in the regulation of Npy gene expression in the ARC, by which FGF11 regulates BAT thermogenesis under HFD conditions.

ARC Fgf11 knockdown in mice fed HFD transiently decreased food intake in our study. A significant decrease in Npy gene expression by ARC Fgf11 knockdown contributed to the induction of PVN TH expression, which regulates BAT thermogenesis rather than reduction of food intake. NPY derived from the ARC regulates BAT thermogenesis via a relay of tyrosine hydroxylase in the PVN through the sympathetic output [28]. Accordingly, substantial weight loss caused by the ARC Fgf11 knockdown may be attributed to increased energy expenditure through BAT thermogenesis.

We demonstrated that FGF11 in the ARC plays a role in the energy balance by regulating Npy expression and affecting BAT thermogenesis and body weight (Summarized in Fig. 7). FGF11 silencing in the ARC increases BAT thermogenesis and energy expenditure by downregulating Npy, which overcomes energy surplus and improves the obese phenotypes under HFD conditions. The delineation of the central role of hypothalamic FGF11 in the regulation of bodily metabolism extends our understanding of the biological functions of FGF11. Overall, our study highlights the importance of FGF11 as a potential therapeutic target for the treatment of obesity.

Fig. 7
figure 7

Schematic diagram of Fgf11 knockdown in prevention of obesity. Fgf11 knockdown increases tyrosine phosphorylation of GSK3α and GSK3β, thereafter reducing CREB phosphorylation to decrease NPY expression. This results in a reduction of NPY projection into the TH neurons in the PVN, leading to increased TH expression. Consequently, TH induction elevates BAT thermogenesis, reducing body weight

Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.





Agouti-related peptide


Arcuate nucleus of the hypothalamus


Brown adipose tissue


Cocaine- and amphetamine-regulated transcript


Ca2+/calmodulin-dependent protein kinase II


CAMP response element–binding protein


Iodothyronine deiodinase 2


Extracellular signal–regulated kinase


Fibroblast growth factor


Fibroblast growth factor receptor


Forkhead box protein O1


Glyceraldehyde 3-phosphate dehydrogenase


Glycogen synthase kinase-3 alpha


Glycogen synthase kinase-3 beta


Glucose tolerance test


Human influenza hemagglutinin


High-fat diet


Intracellular FGF


Insulin tolerance test


Normal-chow diet


Neuropeptide Y


Peroxisome proliferator–activated receptor gamma coactivator 1-alpha




PR domain–containing 16


Paraventricular nucleus of the hypothalamus


Signal transducer and activator of transcription 3


Uncoupling protein-1


  1. Hruby A, Hu FB. The epidemiology of obesity: a big picture. Pharmacoeconomics. 2015;33:673–89.

    PubMed  PubMed Central  Article  Google Scholar 

  2. Malik VS, Willet WC, Hu FB. Nearly a decade on - trends, risk factors and policy implications in global obesity. Nat Rev Endocrinol. 2020;16:615–6.

    PubMed  PubMed Central  Article  Google Scholar 

  3. Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215–66.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  4. Nies VJ, Sancar G, Liu W, van Zutphen T, Struik D, Yu RT, et al. Fibroblast Growth Factor Signaling in Metabolic Regulation. Front Endocrinol (Lausanne). 2015;6:193.

    Google Scholar 

  5. Wiedlocha A, Sorensen V. Signaling, internalization, and intracellular activity of fibroblast growth factor. Curr Top Microbiol Immunol. 2004;286:45–79.

    CAS  PubMed  Google Scholar 

  6. Zhang X, Bao L, Yang L, Wu Q, Li S. Roles of intracellular fibroblast growth factors in neural development and functions. Sci China Life Sci. 2012;55:1038–44.

    CAS  PubMed  Article  Google Scholar 

  7. Marcelin G, Jo YH, Li X, Schwartz GJ, Zhang Y, Dun NJ, et al. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol Metab. 2014;3:19–28.

    CAS  PubMed  Article  Google Scholar 

  8. Morton GJ, Matsen ME, Bracy DP, Meek TH, Nguyen HT, Stefanovski D, et al. FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest. 2013;123:4799–808.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  9. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012;26:271–81.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. Yilmaz U, Tekin S, Demir M, Cigremis Y, Sandal S. Effects of central FGF21 infusion on the hypothalamus-pituitary-thyroid axis and energy metabolism in rats. J Physiol Sci. 2018;68:781–8.

    CAS  PubMed  Article  Google Scholar 

  11. Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, et al. A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature. 2012;485:391–4.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. Hanai K, Oomura Y, Kai Y, Nishikawa K, Shimizu N, Morita H, et al. Central action of acidic fibroblast growth factor in feeding regulation. Am J Physiol. 1989;256:R217–23.

    CAS  PubMed  Google Scholar 

  13. Lee KW, Yim HS, Shin J, Lee C, Lee JH, Jeong JY. FGF11 induced by hypoxia interacts with HIF-1alpha and enhances its stability. FEBS Lett. 2017;591:348–57.

    CAS  PubMed  Article  Google Scholar 

  14. Lee KW, Jeong JY, An YJ, Lee JH, Yim HS. FGF11 influences 3T3-L1 preadipocyte differentiation by modulating the expression of PPARgamma regulators. FEBS Open Bio. 2019;9:769–80.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. Timper K, Bruning JC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech. 2017;10:679–89.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  16. Koch M, Horvath TL. Molecular and cellular regulation of hypothalamic melanocortin neurons controlling food intake and energy metabolism. Mol Psychiatry. 2014;19:752–61.

    CAS  PubMed  Article  Google Scholar 

  17. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci. 1998;1:271–2.

    CAS  PubMed  Article  Google Scholar 

  18. Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci U S A. 1998;95:15043–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med. 1999;5:1066–70.

    CAS  PubMed  Article  Google Scholar 

  20. Rogge G, Jones D, Hubert GW, Lin Y, Kuhar MJ. CART peptides: regulators of body weight, reward and other functions. Nat Rev Neurosci. 2008;9:747–58.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. Coll AP, Farooqi IS, Challis BG, Yeo GS, O’Rahilly S. Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab. 2004;89:2557–62.

    CAS  PubMed  Article  Google Scholar 

  22. Hermes SM, Mitchell JL, Aicher SA. Most neurons in the nucleus tractus solitarii do not send collateral projections to multiple autonomic targets in the rat brain. Exp Neurol. 2006;198:539–51.

    PubMed  Article  Google Scholar 

  23. Larsen PJ, Hay-Schmidt A, Mikkelsen JD. Efferent connections from the lateral hypothalamic region and the lateral preoptic area to the hypothalamic paraventricular nucleus of the rat. J Comp Neurol. 1994;342:299–319.

    CAS  PubMed  Article  Google Scholar 

  24. Huang Y, Lin X, Lin S. Neuropeptide Y and metabolism syndrome: an update on perspectives of clinical therapeutic intervention strategies. Front Cell Dev Biol. 2021;9: 695623.

    PubMed  PubMed Central  Article  Google Scholar 

  25. Morton GJ, Schwartz MW. The NPY/AgRP neuron and energy homeostasis. Int J Obes Relat Metab Disord. 2001;25(Suppl 5):S56-62.

    CAS  PubMed  Article  Google Scholar 

  26. Engstrom Ruud L, Pereira MMA, de Solis AJ, Fenselau H, Bruning JC. NPY mediates the rapid feeding and glucose metabolism regulatory functions of AgRP neurons. Nat Commun. 2020;11:442.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  27. Morselli LL, Claflin KE, Cui H, Grobe JL. Control of energy expenditure by AgRP neurons of the arcuate nucleus: neurocircuitry, signaling pathways, and angiotensin. Curr Hypertens Rep. 2018;20:25.

    PubMed  PubMed Central  Article  Google Scholar 

  28. Shi YC, Lau J, Lin Z, Zhang H, Zhai L, Sperk G, et al. Arcuate NPY controls sympathetic output and BAT function via a relay of tyrosine hydroxylase neurons in the PVN. Cell Metab. 2013;17:236–48.

    CAS  PubMed  Article  Google Scholar 

  29. Oh TS, Cho H, Cho JH, Yu SW, Kim EK. Hypothalamic AMPK-induced autophagy increases food intake by regulating NPY and POMC expression. Autophagy. 2016;12:2009–25.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. Ichim CV, Wells RA. Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation. J Transl Med. 2011;9:137.

    PubMed  PubMed Central  Article  Google Scholar 

  31. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc. 2006;1:241–5.

    CAS  PubMed  Article  Google Scholar 

  32. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15-26.

    CAS  PubMed  Article  Google Scholar 

  33. Ayala JE, Samuel VT, Morton GJ, Obici S, Croniger CM, Shulman GI, et al. Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mice. Dis Model Mech. 2010;3:525–34.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  34. Lee J, Kim K, Cho JH, Bae JY, O’Leary TP, Johnson JD, et al. Insulin synthesized in the paraventricular nucleus of the hypothalamus regulates pituitary growth hormone production. JCI Insight. 2020.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Joly-Amado A, Cansell C, Denis RG, Delbes AS, Castel J, Martinez S, et al. The hypothalamic arcuate nucleus and the control of peripheral substrates. Best Pract Res Clin Endocrinol Metab. 2014;28:725–37.

    PubMed  Article  Google Scholar 

  36. Varela L, Horvath TL. Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis. EMBO Rep. 2012;13:1079–86.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. Burke LK, Darwish T, Cavanaugh AR, Virtue S, Roth E, Morro J, et al. mTORC1 in AGRP neurons integrates exteroceptive and interoceptive food-related cues in the modulation of adaptive energy expenditure in mice. Elife. 2017.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Harno E, Gali Ramamoorthy T, Coll AP, White A. POMC: the Physiological Power of Hormone Processing. Physiol Rev. 2018;98:2381–430.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. Kim EK, Miller I, Aja S, Landree LE, Pinn M, McFadden J, et al. C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem. 2004;279:19970–6.

    CAS  PubMed  Article  Google Scholar 

  40. Kim MS, Pak YK, Jang PG, Namkoong C, Choi YS, Won JC, et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neurosci. 2006;9:901–6.

    CAS  PubMed  Article  Google Scholar 

  41. Ropelle ER, Pauli JR, Prada P, Cintra DE, Rocha GZ, Moraes JC, et al. Inhibition of hypothalamic Foxo1 expression reduced food intake in diet-induced obesity rats. J Physiol. 2009;587:2341–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  42. Kaelin CB, Gong L, Xu AW, Yao F, Hockman K, Morton GJ, et al. Signal transducer and activator of transcription (stat) binding sites but not stat3 are required for fasting-induced transcription of agouti-related protein messenger ribonucleic acid. Mol Endocrinol. 2006;20:2591–602.

    CAS  PubMed  Article  Google Scholar 

  43. Jeon Y, Aja S, Ronnett GV, Kim EK. D-chiro-inositol glycan reduces food intake by regulating hypothalamic neuropeptide expression via AKT-FoxO1 pathway. Biochem Biophys Res Commun. 2016;470:818–23.

    CAS  PubMed  Article  Google Scholar 

  44. Wang H, Xu J, Lazarovici P, Quirion R, Zheng W. cAMP response element-binding protein (CREB): a possible signaling molecule link in the pathophysiology of schizophrenia. Front Mol Neurosci. 2018;11:255.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  45. Parker D, Ferreri K, Nakajima T, LaMorte VJ, Evans R, Koerber SC, et al. Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism. Mol Cell Biol. 1996;16:694–703.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. Fiol CJ, Williams JS, Chou CH, Wang QM, Roach PJ, Andrisani OM. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J Biol Chem. 1994;269:32187–93.

    CAS  PubMed  Article  Google Scholar 

  47. Lin RZ, Chen J, Hu ZW, Hoffman BB. Phosphorylation of the cAMP response element-binding protein and activation of transcription by alpha1 adrenergic receptors. J Biol Chem. 1998;273:30033–8.

    CAS  PubMed  Article  Google Scholar 

  48. Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114–31.

    CAS  PubMed  Article  Google Scholar 

  49. Peltier J, O’Neill A, Schaffer DV. PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. Dev Neurobiol. 2007;67:1348–61.

    CAS  PubMed  Article  Google Scholar 

  50. Grimes CA, Jope RS. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J Neurochem. 2001;78:1219–32.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  51. Yan X, Liu J, Ye Z, Huang J, He F, Xiao W, et al. CaMKII-mediated CREB phosphorylation is involved in Ca2+-induced BDNF mRNA transcription and neurite outgrowth promoted by electrical stimulation. PLoS ONE. 2016;11: e0162784.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  52. Impey S, Obrietan K, Wong ST, Poser S, Yano S, Wayman G, et al. Cross talk between ERK and PKA is required for Ca2+ stimulation of CREB-dependent transcription and ERK nuclear translocation. Neuron. 1998;21:869–83.

    CAS  PubMed  Article  Google Scholar 

  53. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 2004;25:471–80.

    CAS  PubMed  Article  Google Scholar 

  54. Silva-Garcia O, Rico-Mata R, Maldonado-Pichardo MC, Bravo-Patino A, Valdez-Alarcon JJ, Aguirre-Gonzalez J, et al. Glycogen synthase kinase 3alpha is the main isoform that regulates the transcription factors nuclear factor-kappa B and cAMP response element binding in bovine endothelial cells infected with Staphylococcus aureus. Front Immunol. 2018;9:92.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  55. Tseng AS, Engel FB, Keating MT. The GSK-3 inhibitor BIO promotes proliferation in mammalian cardiomyocytes. Chem Biol. 2006;13:957–63.

    CAS  PubMed  Article  Google Scholar 

  56. Cao H, Chu Y, Lv X, Qiu P, Liu C, Zhang H, et al. GSK3 inhibitor-BIO regulates proliferation of immortalized pancreatic mesenchymal stem cells (iPMSCs). PLoS ONE. 2012;7: e31502.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  57. Lee J, Kim K, Yu SW, Kim EK. Wnt3a upregulates brain-derived insulin by increasing NeuroD1 via Wnt/beta-catenin signaling in the hypothalamus. Mol Brain. 2016;9:24.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  58. Konner AC, Bruning JC. Selective insulin and leptin resistance in metabolic disorders. Cell Metab. 2012;16:144–52.

    PubMed  Article  CAS  Google Scholar 

  59. Loh K, Herzog H, Shi YC. Regulation of energy homeostasis by the NPY system. Trends Endocrinol Metab. 2015;26:125–35.

    CAS  PubMed  Article  Google Scholar 

  60. Loh K, Zhang L, Brandon A, Wang Q, Begg D, Qi Y, et al. Insulin controls food intake and energy balance via NPY neurons. Mol Metab. 2017;6:574–84.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  61. Kaminskas B, Goodman T, Hagan A, Bellusci S, Ornitz DM, Hajihosseini MK. Characterisation of endogenous players in fibroblast growth factor-regulated functions of hypothalamic tanycytes and energy-balance nuclei. J Neuroendocrinol. 2019;31: e12750.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  62. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell. 2001;7:1321–7.

    CAS  PubMed  Article  Google Scholar 

  63. Hur EM, Zhou FQ. GSK3 signalling in neural development. Nat Rev Neurosci. 2010;11:539–51.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  64. Wang CY, Liao JK. A mouse model of diet-induced obesity and insulin resistance. Methods Mol Biol. 2012;821:421–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references


This work was supported by the research project entitled “Development of biomedical materials based on marine proteins” (the Ministry of Oceans and Fisheries, Republic of Korea).

Author information

Authors and Affiliations



EKK and JHC conceived and designed the experiments. JHC, KK, CHC and JL performed the experiments. EKK, JHC, KK and CHC analyzed and interpreted the data and edited the manuscript. EKK and JHC wrote the manuscript with input from all authors. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Eun-Kyoung Kim.

Ethics declarations

Ethics approval and consent to participate

All animal procedures and experiments were performed in accordance with the Institutional Animal Care and Use Committee of the Daegu Gyeongbuk Institute of Science and Technology.

Consent for publication

Not applicable.

Competing interests

The authors have declared that no conflict of interest exists.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

Central distribution of Fgf11 mRNA. Figure S2. Hypothalamic Fgf11 mRNA expression following HFD feeding. Figure S3. Effect of Fgf11 knockdown on neuropeptide mRNA expression in the ARC. Figure S4. A representative confocal image of double immunostaining for NPY and TH in the PVN of NCD-fed mice. Figure S5. Neuropeptide mRNA expression after Fgf11 knockdown in POMC/CART co-expressing cells. Figure S6. Effect of fasting on Fgf11 mRNA expression in the hypothalamus. Figure S7. Phosphorylation of upstream kinases of GSK3 after Fgf11 knockdown in NPY/AgRP co-expressing cells.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cho, J.H., Kim, K., Cho, H.C. et al. Silencing of hypothalamic FGF11 prevents diet-induced obesity. Mol Brain 15, 75 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Fibroblast growth factor 11
  • Neuropeptide Y
  • Hypothalamus
  • Arcuate nucleus
  • Brown adipose tissue
  • Thermogenesis
  • Obesity